Format

Send to

Choose Destination
Clin Infect Dis. 2005 Sep 1;41(5):754-7. Epub 2005 Jul 20.

Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

Author information

1
Division of Infectious Diseases, Department of Pharmacy, Singapore General Hospital, Singapore. gpaklh@sgh.com.sg

Abstract

Twenty-one patients with multidrug-resistant (MDR) Acinetobacter baumannii and Pseudomonas aeruginosa pneumonia were treated with nebulized polymyxin E (colistin). Overall clinical and microbiological response rates were 57.1% and 85.7%, respectively. Nebulized colistin may be reasonably efficacious and safe for treatment of MDR pneumonia. Its role in therapy warrants further investigation in comparative studies.

PMID:
16080101
DOI:
10.1086/432583
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center